Growth of Global Parkinson’s Disease Therapeutics Market due to Rising Prevalence of PD

Published Date : Apr 04, 2016

ALBANY, New York, April 04, 2016- has announced the addition of the “Parkinson’s Disease Therapeutics In Major Developed Markets To 2021: Early Pipeline Shifts Towards Disease-Modifying Therapies, While Short Term Growth Driven By Long-Acting Symptomatic Treatments” report to its offering. This market research report on Parkinson’s disease therapeutics explores the evolving landscape of the industry. The report analyzes important market aspects, the growth dynamics of the market, and studies the underlying growth opportunities. The report begins with an overview of Parkinson’s disease, including its symptoms, diagnosis, treatment options, stages, etiology, pathophysiology, epidemiology, and the complications arising from it.

The report’s next segment comprises a study of pharmacological therapies, non-pharmacological treatments, the treatment algorithm used to treat PD, and an overview of early Parkinson’s disease and advanced Parkinson’s disease. The report also gives important figures pertaining to the global Parkinson’s disease therapeutics industry. Marketed products are thoroughly analyzed and dopamine replacement therapies, dopamine agonists, MAO-B inhibitors, COMT inhibitors, and other drugs targeting non-motor symptoms of Parkinson’s disease are studied in detail. A comparative efficacy and safety reports is also given in the report, so as to give a better understanding of the effects of the therapies.

Details of pipeline therapeutics for Parkinson’s disease, with information about clinical trials, failure rates, clinical trial duration, clinical trial size, comparison of average trial metrics, and promising pipeline molecules, are presented. Strategic consolidations and major licensing deals are given in the report.

For Sample Copy, click here:

Parkinson’s disease (PD) is a chronic and progressive disease of the nervous system, affecting a large number of middle-aged and elderly people. Symptoms of Parkinson’s disease include tremors, rigidity of muscles, and slow and imprecise movements. According to the report, the global prevalence of PD in 2011 was 16.1 mn, second only to Alzheimer’s disease among progressive nervous diseases. Parkinson’s disease may not be fatal immediately, but it causes depression, dementia, hallucinations, and loss of taste and smell, which could degrade the quality of a patient’s life.

The report analyzes several drug classes available to relieve the conditions of a patient. With the aim to increase the dopamine levels of a patient, which are diminished due to PD, various therapies such as dopamine agonists, levodopa, and monoamine oxidase-B (MAO-B) inhibitors are available and can be administered as per the patient’s individual condition. However, despite the availability of these therapies, Parkinson’s disease still remains one of the incurable disorders. The current Parkinson’s disease market majorly focuses only on providing symptomatic relief to the patients. This is due to the failure to recognize and identify the underlying causes of the disease. The scope of a viable therapeutic target to slow down or stop the progression of the disease is very less, thus limiting the effectiveness of current developmental programs in treating Parkinson’s disease.

Some of the leading players in the market are: Dainippon Sumitomo Pharma, Cephalon, MedGenesis Therapeutix, Dexcel Pharma, Neuropore Therapies, and Catalent Pharma Solutions, among others.

To order report Call Toll Free: 866-997-4948 or send an email on